Jennifer Lachey
Chief Tech/Sci/R&D Officer bei KEROS THERAPEUTICS, INC.
Profil
Jennifer Lachey's current job is Senior Vice President-Research at Keros Therapeutics, Inc. Her former jobs include being an Associate Director-Preclinical Pharmacology at Acceleron Pharma, Inc. from 2008 to 2012, a Senior Director at Seres Therapeutics, Inc. from 2015 to 2016, and a Senior Director-Preclinical Pharmacology at Ember Therapeutics, Inc. from 2012 to 2015.
Dr. Lachey obtained her undergraduate degree from Indiana University and her doctorate degree from the University of Cincinnati (Ohio).
Aktive Positionen von Jennifer Lachey
| Unternehmen | Position | Beginn |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.06.2019 |
Ehemalige bekannte Positionen von Jennifer Lachey
| Unternehmen | Position | Ende |
|---|---|---|
| SERES THERAPEUTICS, INC. | Director/Board Member | 01.07.2016 |
| EMBER THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2015 |
| ACCELERON PHARMA INC. | Corporate Officer/Principal | 01.07.2012 |
Ausbildung von Jennifer Lachey
| Indiana University | Undergraduate Degree |
| University of Cincinnati (Ohio) | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SERES THERAPEUTICS, INC. | Health Technology |
| EMBER THERAPEUTICS, INC. | Health Technology |
| KEROS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
